We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders PR Newswire NEW YORK, March 18, 2021 NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition...
Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma PR Newswire NEW...
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program PR Newswire NEW YORK, Feb. 3, 2021 NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation...
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative PR Newswire NEW YORK, Dec. 21, 2020 NEW YORK, Dec. 21, 2020 /PRNewswire/...
Longevity Acquisition Corporation Regains Compliance with Nasdaq Listing Requirement PR Newswire NEW YORK, Dec. 11, 2020 NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Longevity Acquisition Corporation...
Longevity Acquisition Corporation Announces Extension of Deadline to Complete a Business Combination PR Newswire NEW YORK, Nov. 20, 2020 NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Longevity...
Longevity Acquisition Corporation Announces Increased Cash Contribution for the Extension PR Newswire NEW YORK, Nov. 17, 2020 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Longevity Acquisition...
Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement PR Newswire SHANGHAI, Oct. 22, 2020 SHANGHAI, Oct. 22, 2020 /PRNewswire/ -- Longevity Acquisition Corporation...
Longevity Acquisition Corporation Announces Extension of Deadline to Complete a Business Combination PR Newswire NEW YORK, May 22, 2020 NEW YORK, May 22, 2020 /PRNewswire/ -- Longevity...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions